Chief Medical Officer · Stoke Therapeutics, Inc. (STOK)

Barry Ticho

A named executive officer of Stoke Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,469,437

Salary $514,030Stock awards $1,133,600

FY2023: $1,648,007

3rd of 3 named executive officers at Stoke Therapeutics by FY2024 total.

3 named officers on file for Stoke Therapeutics, FY2024

Barry Ticho’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • STOK’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Stoke Therapeutics’s whole pay program stands against its peers

  • Stoke Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STOK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Barry Ticho’s full pay file as a PDF — free

More than this page: up to 10 years of Barry’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barry Ticho compensation by year

Stoke Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Stoke Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024
Salary$428,800$448,308$470,723$494,259$514,030
Bonus$8,576$8,966$20,712$0$0
Stock awards$0$0$0$489,272$1,133,600
Option awards$1,215,000$2,484,499$1,697,431$474,186$609,336
Non-equity incentive$214,400$197,257$186,407$177,934$205,612
Pension and deferred compensation$0$0$0$0$0
All other$10,720$10,461$10,984$12,356$6,859
Total$1,877,496$3,149,491$2,386,257$1,648,007$2,469,437

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Stoke Therapeutics, Inc. DEF 14A filed April 22, 2025, accession 0001193125-25-089188, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Stoke Therapeutics, Inc. filed document, accession 0001193125-25-089188. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2025.

$1.9M
$3.1M
$2.4M
$1.6M
$2.5M
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU40,000$441,200—
RSU39,300$433,479—
PSU20,000$220,600—
RSU11,981$132,150—
RSU10,000$110,300—
Option31,000—$7.07
Option44,213—$9.15
Option48,750—$14.17

Per the Outstanding Equity Awards at Fiscal Year-End table in Stoke Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

60 Form 4 lines since the FY2024 proxy (filed April 22, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-02Sale10b5-16,995$26.3812,064
2026-11-02Sale10b5-1200$26.9911,864
2026-10-01Sale10b5-11,051$26.1619,059
2026-09-01Sale10b5-11,600$31.0620,110
2026-09-01Sale10b5-13,945$30.5121,710
2026-08-18Sale—4,525$32.0125,897
2026-08-18Sale—242$32.4725,655
2026-08-14Exercise or conversion—10,000$0.0030,422

The 8 most recent of 60 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Stoke Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Edward KayeChief Executive Officer$5,612,120
Thomas LeggettChief Financial Officer$4,520,386
Barry Ticho · this pageChief Medical Officer$2,469,437

The full Stoke Therapeutics compensation record

free company brief

This page is one person within Stoke Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Stoke Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Stoke Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barry Ticho's compensation dossier · One-time report. No refunds.